Asporin is a Potential Promising Biomarker for Common Heart Failure

Kai Zhang1, Min Wu1, Xianyu Qin1

  • 1Guangdong Provincial Key Laboratory of South China Structural Heart Disease, Department of Cardiovascular Surgery, Guangdong Cardiovascular Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, School of Medicine, South China University of Technology, Guangzhou, China.

DNA and Cell Biology
|February 19, 2021
PubMed

Insights

This study identified common molecular mechanisms in heart failure (HF) from ischemic and dilated cardiomyopathy. Asporin (ASPN) protein was found to be elevated in HF patients, suggesting its potential as a novel heart failure biomarker.

Area of Science:

  • Cardiovascular Biology
  • Molecular Medicine
  • Genomics

Background:

  • Heart failure (HF) is a critical end-stage condition for diseases like ischemic cardiomyopathy (ICM) and dilated cardiomyopathy (DCM).
  • Understanding the shared molecular underpinnings of different HF etiologies is crucial for developing effective treatments.

Purpose of the Study:

  • To investigate the common molecular mechanisms underlying ICM and DCM.
  • To identify potential molecular biomarkers for heart failure.

Main Methods:

  • Differential gene expression analysis across multiple public datasets (GSE1869, GSE5406, GSE57338, GSE79962, GSE116250, GSE46224).
  • Functional enrichment and protein-protein network analyses using DAVID, Metascape, and STRING.
  • Identification and validation of hub genes via western blotting (WB) and tissue microarray (TMA).

Main Results:

  • Identified 74 coregulated DEGs for ICM and 126 for DCM, with 59 common genes.
  • Common genes are implicated in cardiac fibrosis and signaling pathways (Wnt, PI3K-Akt, HIF-1A).
  • Asporin (ASPN) emerged as a key hub gene, correlating with LVEF, and was significantly upregulated in ICM and DCM left ventricular tissues.

Conclusions:

  • The study reveals shared molecular mechanisms in heart failure regardless of underlying cause.
  • Asporin (ASPN) is a promising potential biomarker for heart failure diagnosis and management.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
331
Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
530
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
210
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
553
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
88
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
666